Mineralys Therapeutics, INC. (MLYS) — 8-K Filings

8-K Filings (18)

• Mineralys Therapeutics Files 8-K — Sep 3, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting other events and financial statements. The filing details the company's incorporation
• Mineralys Therapeutics Files 8-K — Sep 2, 2025 Risk: medium
  Mineralys Therapeutics, Inc. filed an 8-K on September 2, 2025, to report "Other Events." The filing does not contain specific details about the nature of these
• Mineralys Therapeutics Files 8-K — Jun 17, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting on several items including Regulation FD Disclosure, Other Events, and Financial Statement
• Mineralys Therapeutics Files 8-K — May 22, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting the submission of matters to a vote of security holders and financial statements and exhibi
• Mineralys Therapeutics Files 8-K — Mar 31, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on March 31, 2025, reporting events that occurred on March 29, 2025. The filing includes information related to Regula
• Mineralys Therapeutics Files 8-K — Mar 12, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on March 12, 2025, reporting on events that occurred on March 11, 2025. The filing primarily concerns "Other Events" a
• Mineralys Therapeutics Files 8-K — Mar 10, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on March 10, 2025, to report on various events. The filing includes information related to Regulation FD Disclosure, O
• Mineralys Therapeutics Files 8-K — Feb 4, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on February 4, 2025, to report on other events and financial statements. The filing does not contain specific financia
• Mineralys Therapeutics Files 8-K — Jan 8, 2025 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on January 8, 2025, to report on other events and financial statements. The filing does not contain specific financial
• Mineralys Therapeutics Files 8-K — Oct 30, 2024 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on October 30, 2024, to report on other events and financial statements. The filing does not contain specific details
• Mineralys Therapeutics Files 8-K — Sep 25, 2024 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on September 25, 2024, to report on other events and financial statements. The filing does not contain specific financ
• Mineralys Therapeutics Appoints New Directors, Updates Executive Contracts — Jun 14, 2024 Risk: low
  Mineralys Therapeutics, Inc. announced on June 13, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company el
• Mineralys Therapeutics Files 8-K — Jun 10, 2024 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its prin
• Mineralys Therapeutics Files 8-K — May 31, 2024 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on May 31, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures o
• Mineralys Therapeutics Reports on Shareholder Votes — May 22, 2024 Risk: low
  Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Mineralys Therapeutics Announces Board and Executive Changes — Apr 4, 2024 Risk: medium
  Mineralys Therapeutics, Inc. announced on March 29, 2024, changes in its board of directors and executive compensation arrangements. The filing details the depa
• MLYS Reports Material Agreement, Unregistered Equity Sales — Feb 8, 2024 Risk: medium
  Mineralys Therapeutics, Inc. (MLYS) filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equit
• Mineralys Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 4, 2024
  Mineralys Therapeutics, Inc. filed an 8-K on January 4, 2024, to report general corporate information and confirm its status as a publicly traded company on The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX